Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages
Authors Yu SS, Lau CM, Thomas SN, Jerome WG, Maron DJ, Dickerson JH, Hubbell JA, Giorgio TD
Received 23 November 2011
Accepted for publication 29 December 2011
Published 15 February 2012 Volume 2012:7 Pages 799—813
DOI https://doi.org/10.2147/IJN.S28531
Review by Single-blind
Peer reviewer comments 4
Shann S Yu1,2, Cheryl M Lau1, Susan N Thomas3, W Gray Jerome4, David J Maron5, James H Dickerson2,6, Jeffrey A Hubbell3, Todd D Giorgio1,2,7,8
1Department of Biomedical Engineering, Vanderbilt University, Nashville, 2Vanderbilt Institute of Nanoscale Science and Engineering, Nashville, TN, USA; 3Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 4Department of Pathology, Vanderbilt University Medical Center, Nashville, 5Vanderbilt Heart and Vascular Institute, Nashville, 6Department of Physics and Astronomy, Vanderbilt University, Nashville, 7Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, 8Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA
Abstract: The assessment of macrophage response to nanoparticles is a central component in the evaluation of new nanoparticle designs for future in vivo application. This work investigates which feature, nanoparticle size or charge, is more predictive of non-specific uptake of nanoparticles by macrophages. This was investigated by synthesizing a library of polymer-coated iron oxide micelles, spanning a range of 30–100 nm in diameter and -23 mV to +9 mV, and measuring internalization into macrophages in vitro. Nanoparticle size and charge both contributed towards non-specific uptake, but within the ranges investigated, size appears to be a more dominant predictor of uptake. Based on these results, a protease-responsive nanoparticle was synthesized, displaying a matrix metalloproteinase-9 (MMP-9)-cleavable polymeric corona. These nanoparticles are able to respond to MMP-9 activity through the shedding of 10–20 nm of hydrodynamic diameter. This MMP-9-triggered decrease in nanoparticle size also led to up to a six-fold decrease in nanoparticle internalization by macrophages and is observable by T2-weighted magnetic resonance imaging. These findings guide the design of imaging or therapeutic nanoparticles for in vivo targeting of macrophage activity in pathologic states.
Keywords: macrophage targeting, poly(ethylene glycol) (PEG), poly(propylene sulfide) (PPS), iron oxides, opsonization
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Readers of this article also read:
Optimal delivery of male breast cancer follow-up care: improving outcomes
Ferzoco RM, Ruddy KJ
Breast Cancer: Targets and Therapy 2015, 7:371-379
Published Date: 23 November 2015
Advances in cancer pain from bone metastasis
Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY
Drug Design, Development and Therapy 2015, 9:4239-4245
Published Date: 18 August 2015
Clinical utilities of aromatase inhibitors in breast cancer
Chumsri S
International Journal of Women's Health 2015, 7:493-499
Published Date: 6 May 2015
Targeting the hypoxia pathway to treat pancreatic cancer
Erickson LA, Highsmith Jr WE, Fei P, Zhang J
Drug Design, Development and Therapy 2015, 9:2029-2031
Published Date: 8 April 2015
Clinical epidemiology of epithelial ovarian cancer in the UK
Doufekas K, Olaitan A
International Journal of Women's Health 2014, 6:537-545
Published Date: 23 May 2014
Ulcerative colitis six years after colon cancer: only a coincidence?
Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H
International Medical Case Reports Journal 2014, 7:85-88
Published Date: 29 April 2014
Oncolytic viral therapy for pancreatic cancer: current research and future directions
Ady JW, Heffner J, Klein E, Fong Y
Oncolytic Virotherapy 2014, 3:35-46
Published Date: 17 February 2014
Implications for breast cancer dormancy in other areas of medicine
Rameshwar P
Breast Cancer: Targets and Therapy 2012, 4:193-195
Published Date: 5 December 2012
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Yee AJ, Raje NS
Clinical Interventions in Aging 2012, 7:331-338
Published Date: 3 September 2012
Capecitabine in the management of colorectal cancer
Hirsch BR, Zafar SY
Cancer Management and Research 2011, 3:79-89
Published Date: 24 March 2011
